Averto Medical Debuts with Oversubscribed $30M Series A Financing to Advance Innovative Medical Device that Avoids Need for Ostomy
Cormorant Asset Management leads financing with participation from Venrock Healthcare Capital Partners, LifeSci Venture Partners, CVF, and others; Ken Song, MD joins as Executive Chairman with Dan Puckett and Bihua Chen also joining the Board of Directors
SAN FRANCISCO, May 7, 2024 /PRNewswire/ — Averto Medical Inc (“Averto”, “The Company”), a clinical-stage medical device company pioneering minimally invasive gastrointestinal care, today announced the closing of an oversubscribed $30.5 million Series A financing. Cormorant Asset Management led the financing with participation from Venrock Healthcare Capital Partners, LifeSci Venture Partners, CVF, and other investors.
